Halozyme Therapeutics Inc (HALO)

Currency in USD
62.90
+0.80(+1.29%)
Closed·
After Hours
63.10+0.20(+0.32%)
·
HALO Scorecard
Full Analysis
Has a perfect Piotroski Score of 9
HALO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
61.9063.27
52 wk Range
42.0170.50
Key Statistics
Prev. Close
62.1
Open
61.97
Day's Range
61.9-63.27
52 wk Range
42.01-70.5
Volume
1.59M
Average Volume (3m)
2.48M
1-Year Change
15.5%
Book Value / Share
2.7
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HALO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
69.78
Upside
+10.93%
Members' Sentiments
Bearish
Bullish
ProTips
Management has been aggressively buying back shares

Halozyme Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Halozyme Therapeutics Inc Company Profile

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Employees
350

Halozyme Therapeutics Inc Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of $1.54 beat forecasts by 24.19%, while revenue of $206M missed by 27.97%
  • Royalty revenue grew 65% YoY to $206M, driven by strong ENHANZE technology performance
  • 2025 total revenue guidance raised to $1.275-$1.355B, projecting 26-33% growth
  • Stock rose 1.37% after-hours despite revenue miss, reflecting positive investor sentiment
  • CEO highlighted broad growth catalysts; CFO emphasized commitment to share repurchases
Last Updated: 05/08/2025, 23:12
Read Full Transcript

Compare HALO to Peers and Sector

Metrics to compare
HALO
Peers
Sector
Relationship
P/E Ratio
13.2x−1.7x−0.5x
PEG Ratio
0.19−0.100.00
Price/Book
22.1x2.7x2.6x
Price / LTM Sales
6.2x9.5x3.3x
Upside (Analyst Target)
19.2%318.4%43.5%
Fair Value Upside
Unlock7.1%6.8%Unlock

Analyst Ratings

6 Buy
3 Hold
1 Sell
Ratings:
10 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 69.78
(+10.93% Upside)

Earnings

Latest Release
Aug 05, 2025
EPS / Forecast
1.54 / 1.24
Revenue / Forecast
326.00M / 286.01M
EPS Revisions
Last 90 days

HALO Income Statement

People Also Watch

37.72
EXEL
+0.88%
103.82
CRUS
+3.16%
247.45
AVAV
-4.68%
32.02
YOU
+0.28%
133.24
FI
+0.41%

FAQ

What Stock Exchange Does Halozyme Trade On?

Halozyme is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Halozyme?

The stock symbol for Halozyme is "HALO."

What Is the Halozyme Market Cap?

As of today, Halozyme market cap is 7.36B.

What Is Halozyme's Earnings Per Share (TTM)?

The Halozyme EPS (TTM) is 4.48.

When Is the Next Halozyme Earnings Date?

Halozyme will release its next earnings report on 09 Nov 2025.

From a Technical Analysis Perspective, Is HALO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Halozyme Stock Split?

Halozyme has split 1 times.

How Many Employees Does Halozyme Have?

Halozyme has 350 employees.

What is the current trading status of Halozyme (HALO)?

As of 09 Aug 2025, Halozyme (HALO) is trading at a price of 62.90, with a previous close of 62.10. The stock has fluctuated within a day range of 61.90 to 63.27, while its 52-week range spans from 42.01 to 70.50.

What Is Halozyme (HALO) Price Target According to Analysts?

The average 12-month price target for Halozyme is USD69.77778, with a high estimate of USD91 and a low estimate of USD51. 6 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +10.93% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.